Pharmaron Beijing Co., Ltd.

Equities

300759

CNE100003JW4

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
20.43 CNY +1.14% Intraday chart for Pharmaron Beijing Co., Ltd. -10.59% -29.50%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Pharmaron's 2023 Profit, Revenue Rise; Misses Estimates MT
Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2023 CI
Pharmaron Beijing Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Nomura Adjusts Pharmaron Beijing’s Price Target to HK$17.99 From HK$30.92, Keeps at Buy MT
Pharmaron Beijing Sees Up to 14% Jump in 2023 Profit MT
Pharmaron Forecasts Up to 19% Rise in 2023 Attributable Profit MT
Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2023 CI
Pharmaron Beijing Buys Back Additional Series 2 Bonds MT
Pharmaron Beijing Buys Back $68 Million of Convertible Bonds Due 2026 MT
Pharmaron Beijing Buys Back 705 Million Yuan of Series 2 Bonds Due 2026 MT
Pharmaron's Q3 Attributable Profit Rises 6%; Shenzhen Shares Surge 12% MT
Pharmaron Beijing Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Nomura Adjusts Pharmaron’s Price Target to 61.24 Yuan From 66.94 Yuan, Keeps at Buy MT
Pharmaron's Profit Climbs 34.3% in H1 MT
Pharmaron Beijing Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Pharmaron Beijing's Profit to Jump Up to 36% in H1; Shares Jump 10% MT
Pharmaron Slashes Conversion Price of Zero-Coupon Convertible Bonds Due 2026 MT
Nomura Adjusts Pharmaron’s Price Target to 66.94 Yuan From 73.38 Yuan, Keeps at Buy MT
Nomura Adjusts Pharmaron’s Price Target to HK$36.24 From HK$40.03, Keeps at Buy MT
Pharmaron Beijing Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 27, 2023 CI
Pharmaron Beijing Co., Ltd. Approves Cash Dividend for 2022 CI
Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2022, Payable on 18 August 2023 CI
Nomura Adjusts Pharmaron’s Price Target to 73.38 Yuan From 85.63 Yuan, Keeps at Buy MT
Nomura Adjusts Pharmaron's Price Target to HK$60.04 From HK$69.02, Keeps at Buy MT
Pharmaron Beijing Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Chart Pharmaron Beijing Co., Ltd.
More charts
Pharmaron Beijing Co. is specialised in the research, development and manufacturing of small molecule drugs, cell therapies and gene therapies. Net sales break down by activity as follows: - laboratory services (61.3%); - development and production of chemical processes and formulations (23.5%); - clinical research services (12.8%); - other (2.4%); Net sales are distributed geographically as follows: China (17.1%), Asia (2.6%), North America (64.2%), Europe (15.6%) and other (0.5%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
20.43 CNY
Average target price
31.31 CNY
Spread / Average Target
+53.27%
Consensus
  1. Stock
  2. Equities
  3. Stock Pharmaron Beijing Co., Ltd. - Shenzhen S.E.
  4. News Pharmaron Beijing Co., Ltd.
  5. Nomura Adjusts Pharmaron Beijing's Price Target to HK$141.62 From HK$178.52, Keeps at Buy